2025 POSTER PRESENTATIONS

Poster Awards will be announced Tuesday at 2:00pm and Wednesday at 7:00pm.

POSTER SESSION A: Monday - Tuesday (morning)

A001: Prometheus 2.0™: Engineering Manufacturable Humanized Antibodies from Diverse Sources Including Rabbit and Camelid Antibodies, Presented by Catherine B., Absolute Biotech

A002: Identification of Tumor-Specific Antibody Using CAR-Based Cell Display System, Presented by Chia-Wei L., Academia Sinica

A003: De-Risking and Accelerating the Discovery of High-Value Antibodies Through AI-Driven Active Learning and High-Throughput Humanization, Presented by Patrick D., Ailux Biologics by XtalPi

A004: Enhancing TCR Affinity and Maintaining pMHC Specificity Through Structure-Guided Mutagenesis and Yeast Display Screening, Presented by Yvonne F., Ailux Biologics by XtalPi

A005: Skimune®: An In Vitro Human Skin Platform for Immunotoxicity Testing of Novel Therapeutics, Presented by Steven O., Alcyomics Ltd.

A006: Unifying Sequence, Structure and State Data: A Digital Platform for Data Integration and Antibody Engineering, Presented by Alexandra A., Apoha Ltd.

A007: Strategies for Engineering Mammalian Cells to Express Difficult Proteins — 4-6 Weeks from Start to Final Clone or Pool CELL LINE ENG, Presented by Cassandra M., Applied StemCell

A008: Leap-In Transposase®: High Yield Stable Cell Lines with Predictable Antibody Quality and Improved Expression Stability, Presented by Claes G., ATUM

A009: High-Throughput Engineering of Signal Peptides to Maximize Protein Expression, Presented by Khushbu R., Avenue Biosciences

A010: RenNano®-Derived Human Heavy-Chain-Only TFR1 Antibodies Enable Efficient Blood-Brain Barrier Penetration and Therapeutic Delivery, Presented by Hao C., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

A011: BCG028: A Novel Fc-Engineered Biparatopic OX40 Antagonist for Targeted Treatment of Atopic Dermatitis, Presented by Guan W., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

A012: Simplified and Humanized: Empowering Humanized Antibody Discovery with AbDrop™ Solution, Presented by Huanyi Y., Biointron

A013: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform, Presented by Miao L., Bio-Rad Laboratories

A014: Asymmetric bsAbs: A Reliable Platform Solution, Presented by Nick K., Bioworkshops

A015: Rapid, Automated Discovery of VHH Binders with Diverse Epitopes and Affinities, Presented by Stephen J., Broad Institute of MIT and Harvard

A016: Accelerating Biologics Discovery with Comprehensive Biophysical Characterizations of Binding Kinetics, Presented by Sven M., Bruker Biosensors

A017: Accelerating Internalizing Antibody Discovery with Bruker Cellular Analysis Optofluidic Platforms, Presented by Brittany B., Bruker Cellular Analysis

A018: Cryopreservation of Activated Memory B Cells Facilitates Enhanced Flexibility and Throughput for Opto® B Discovery on the Beacon® Optofluidic Systems, Presented by Vincent P., Bruker Cellular Analysis

A019: Full Antigen Kinetics of Fabs Directly from Crude Periplasmic Extracts on an Anti-CH1 Capture Surface, Presented by Chris S., Carterra

A020: Pharmacophore-Guided Virtual Screening of Antibody Formats, Presented by Alain A., Chemical Computing Group

A021: Recombinant G-Protein Coupled Chemokine Receptors CXCR4 and CXCR5 on Nanoparticles are Bioactive, Binding to the Chemokine Ligands, Presented by Tim S., Conigen Bioscience

A022: Novel Soluble Cytokine Receptors IFNγR1 Homodimer and IFNαR1/R2 Heterodimer Enhance Binding to Type II and Type I Interferons Compared to Monomers, Presented by Shixia W., Conigen Bioscience

A023: Rapid Discovery of Antagonistic Human/Cyno CD200R1 Llama VHH Nanobodies Using Single B Cell Technology, Presented by Nicole P., Curia

A024: An Engineered IgG Protease for the Rapid and Sustained Degradation of Autoantibodies, Presented by Erik P., Cyrus Biotechnology

A025: Modular and Nondisturbing Chimeric Adaptor Protein for Surface Chemistry of Small Extracellular Vesicles, Presented by Jiwon S., Daegu Gyeongbuk Institute of Science and Technology

A026: High-Performance Antibody Discovery Using DPBIO CytoSpark Microfluidic Droplet Sorting System, Presented by Jennifer S., Dapu Biotechnology Co., Ltd. (DPBIO)

A027: Epitope Mapping Case Studies by Deep Mutational Scanning, Presented by Tiphanie P., Deeptope

A028: Modulation of Antibodies' Fc Fragment Interaction with Fc Receptors by Deep Mutational Scanning, Presented by Fabien Q., Deeptope

A029: Therapeutic mAb Discovery for Multi-Pass Transmembrane Protein Targets, Presented by Donghui M., DIMA Biotech

A030: Integral Membrane Proteins for Biophysics and Cryo-EM Applications – Case Study of the Ion Channel TrpML3, Presented by Chris M., Domainex Ltd.

A031: Antibody and Therapeutics Discovery: Network and Tree Visualizations for Interrogating Sequence Similarity Between Unique Clones and CDRs in NGS Datasets, Presented by Monica W., Dotmatics

A032: Artificial Expression System for High-Performance Production of Biomedicines: From Concepts to Reality, Presented by Philippe J., Eukarys SAS

A033: Unlocking Agonism: A Comprehensive Strategy to Characterize Agonistic Antibodies for Immunotherapy & Autoimmunity, Presented by Natalie G., Eurofins DiscoverX

A034: Quantitative Measurement of Fc-Mediated ADCC & ADCP Activity of Therapeutic Antibodies Using a Robust, Universal Cell-Based Assay Platform, Presented by Alpana P., Eurofins DiscoverX

A035: Cell-Apalooza: An Anti-T-Cell Immunization Strategy for a Novel, Targeted “AbNano™” Immune-Derived Library, Presented by Sam S., Fortis Life Sciences

A036: Mammalian Display for Antibody Discovery, Presented by Adrian K., Fusion Antibodies PLC

A037: A Rational Affinity Maturation Platform (RAMP™ ), Presented by Richard M., Fusion Antibodies PLC

A038: High-Throughput (HTP) Label-Free Kinetics Screening Using Gator-Pro in Early Single Domain Antibody Discovery: A Comparative Analysis with Phage Display Samples from Periplasma, Presented by Pu L., Gator Bio

A039: Integrated Analysis of Assays Drive Early Developability Assessment of Antibodies, Presented by Charles A., Genedata AG

A040: Accelerating Biopharmaceutical and Vaccine Research, Discovery, and Development, Presented by Jana H., Genedata AG

A041: Revolutionizing Antibody Therapeutics: Harnessing Machine Learning for Bispecific Antibody Discovery, Presented by Crystal R., GENEWIZ from Azenta Life Sciences

A042: Engineering a Next-Generation CRISPR-Repressor for Highly Optimized Cancer Gene Regulation, Presented by Andrew K., Georgia Institute of Technology

A043: Function First Screening Approaches in Antibody Discovery Using the Beacon® Optofluidic System, Presented by Darryl H., GSK

A044: High-Sensitivity MAPPs for Immunogenicity Risk Assessment of Biotherapeutics, Presented by Elise P., ImmuneSpec

A045: Collagen Targeting IL-12 Combined with Doxorubicin Enhances the Anti-Tumour Effect Against Osteosarcoma, Presented by Takumi M., Imperial Collage London

A046: From Target Identification Using Bioinformatics to a Novel Therapeutic Candidate Antibody Targeting CD167a, Presented by Divya A., Indian Institute of Technology Delhi

A047: High-Throughput Discovery of Recombinant Antibodies Against the Semaphorin Family, Presented by Rebecca H., Institute for Protein Innovation

A048: Synthetic Interferon IB-001 Exhibits Potent Antiviral Activity Across both DNA and RNA Viruses with Limited Pro-Inflammatory Gene Induction, Presented by Nathanael S., IntegerBio

A049: Pan-Reactive MAbs Enable Preclinical Animal Models: MAbs for Validating Targets Across Diverse Animal Species, Presented by Ross C., Integral Molecular

A050: Off-Target Binding of Antibody-Based Biologics: A Systematic Evaluation of Drugs Throughout Clinical and Preclinical Development, Presented by Rachel F., Integral Molecular

A051: A Novel IgG-Like Trispecific Antibody Platform to Accelerate Lead Identification, Presented by Nicholas M., Invenra, Inc.

A052: Accelerating Antibody Discovery and Development into the Clinic with Mammalian Display, Presented by Kothai P., Iontas Ltd.

A053: CIS Display™  — The Cell-Free Platform for Enhancing Small-Format Discovery, Presented by Nicola E., Isogenica Ltd.

A054: Biofloating: A Workflow for the Discovery of Antibodies Targeting Multi-Pass Transmembrane Proteins, Presented by Justyn F., Johns Hopkins University

A055: GPCR VLPs & Nanodiscs for Drug Discovery, Presented by Jordan C., KACTUS

A056: Transforming Tumor Research: Engineering MHCs as Versatile Reagents, Presented by Maggie G., KACTUS

A057: Enhancing the Therapeutic Efficacy and Safety of Anti-CTLA4 Antibody in Colorectal Cancer with a Tumor-Activated Interferon Fusion Strategy, Presented by Chih-Hung C., Kaohsiung Medical University

A058: Engineering of Affibody-Based Prodrugs for Cancer Therapy, Presented by Hanna M., KTH Royal Institute of Technology

A059: Development of an Affibody Molecule for Monitoring Immune Cell Activation, Presented by Hugo O., KTH Royal Institute of Technology

A060: Advancing Antibody Discovery with Function-Focused Profiling at the Single-Cell Level, Presented by Simon M., Lightcast

A061: A Novel Single-Cell Selection Platform for Rapid Identification of Antibodies Against Different Antigens from Breast Cancer Patients, Presented by Filipa F., Lxbio

A062: A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity, Presented by Li H., Matwings Technology

A063: High Diversity Phage Display Library for Discovery of High-Affinity VHH, Presented by Carolyn J., Merck & Co., Inc.

A064: Sequence Diversity of Antibody Display Library Identified Through Multiple In-Parallel NGS-Based Phage Pannings, Presented by Oscar P., Merck & Co., Inc.

A065: Durable but Transient Expression of Therapeutic Proteins In Vivo from Plasmid DNA, Presented by Sean K., Nanite, Inc.

A066: Deep Learning of Antibody Epitopes Using Positional Permutation Vectors, Presented by Ioannis V. & Giulia P., NEC Oncoimmunity - a NEC Bio company

A067: Development of Fully Human CD98hc Antibodies to Enhance Delivery of Therapeutic Drugs Across the Blood-Brain Barrier, Presented by Min J., NeoMab Biotechnology Co., Ltd.

A068: Development of Fully Human CD3 Antibodies and CD3/DLL3 TCEs with Potent Cytotoxicity and Reduced Cytokine Release, Presented by Eileen X., NeoMab Biotechnology Co., Ltd.

A069: Rapid DIY Gene Synthesis: From Oligos to Low-Cost Genes with NEBridge® Golden Gate Assembly, Presented by Sean L., New England Biolabs, Inc.

A070: Where Did My Target Go? High-Throughput Plasma Proteomics of Checkpoint Inhibitor Therapy Reveals Regulation of Other Immunotherapy Targets, Presented by Eric M., Nomic Bio

A071: Functional Membrane Proteins - Ready in 48 Hours, Presented by Aujan M., Nuclera

A072: Numaswitch – A Novel Biochemical Platform for Efficient Peptide and Protein Production, Presented by Christian S., NUMAFERM GmbH

A073: Discovery of a Best-in-Class Bispecific TRAILR2 Agonist for Treatment of Gastrointestinal Tumors, Presented by Elaine P., Odyssey Therapeutics

A074: Machine Learning-Driven VHH Design: From Sequence to Binding Data in 5 Days, Presented by Victor B., Ordaos Bio

A075: Integration of a pH-Dependent FcRn Binding Assay into a Suite of Microplate-Based Developability Assays in High-Throughput, Presented by Sebastian G., PAIA Biotech GmbH

A076: Beyond Binding: High-Throughput Functional Screening of Antibody Libraries via Flow Cytometry and Nanovials, Presented by Joseph D., Partillion Bioscience

A077: ALAgene® Technology: Harnessing Chicken Immunity to Generate High-Affinity, Cross-Reactive Antibodies Against Difficult Targets, Presented by Rimpa P., Pharma Foods International Co., Ltd.

A078: Targeting KRAS Mutation Diversity with Epivolve®: A Novel Approach for Precision Cancer Therapeutics and Diagnostics, Presented by Greg M., Precision BioTools

A079: Pfenex Expression Technology® - Scalable Rapid Expression and Affinity Enrichment of Untagged RNA Polymerase Variants from Microtiter Plates, Presented by Jeff A., Primrose Bio

A080: High-Sensitivity Lumit® IgG Titer Assays for Enhanced Quantification and Broad IgG Subclass Detection, Presented by Juliano A., Promega Corporation

A081: Development of Novel Luminescent Assays for Sensitive and Specific Quantitation of Double-Stranded RNA in mRNA Therapeutics, Presented by Kai H., Promega Corporation

A082: High-Throughput Antibody Engineering via Deep Mutational Scanning and Single-Molecule Fluorescence Imaging for Affinity and Developability Optimization, Presented by Jihye J., PROTEINA

A083: Discovery and Characterization of Antibodies Against Challenging Membrane Protein Targets Using Salipro Nano-Membrane Particles, Presented by Peter J., Salipro Biotech AB

A084: Utilizing IMPACT Platform to Engineer Selectivity of Biotherapeutics for Treatment of Autoimmune Diseases, Presented by Grace C., Seismic Therapeutic

A085: Integrating Machine Learning Based Antibody Sequence Generation with Yeast Display Enables High Success Rates of Multi-Objective Drug Design, Presented by Rasika H., Seismic Therapeutic

A086: HC029: A Conformation Selective Integrin β6 ADC, Presented by Teddy Y., Shanghai HongCheng Biopharma

A087: Single Biomarker Cell Mimics for Standardized Monitoring of T-Cell Activation and Exhaustion in Antibody Drug Development, Presented by Sarah K., Slingshot Biosciences

A088: Synthesizing Single-Chain Antibody Libraries Directly on SPOC SPR Biosensor Chips, to Generate High Resolution Kinetic Data at Scale, to Support AI-Drug Design and Affinity Maturation Cycles, Presented by Rebecca C., SPOC Proteomics

A089: Genetically Engineered Liposwitching Protein Nanomaterials, Presented by Alex W., Syracuse University

A090: Antibody Screening Strategies for Lead Identification to Evaluate Inflammatory Pathway Inhibition, Presented by Ashwajith S., Takeda Pharmaceuticals

A091: Leveraging AI-Enhanced Multi-Omics for ADC Development Against a Novel Target in Lung Cancer, Presented by Daniel M. & Christoph M., TenSixty Bio

A092: Macrocyclization and Genetic Code Expansion of Phage-Displayed Peptide Libraries, Presented by Joshua H., Texas A&M University

A093: Expi293™ PRO Expression System: Expression Improvements Across Different Classes of Proteins, Product Quality Assessment and Purification Compatibility, Presented by Kyle W., Thermo Fisher Scientific

A094: Scalable Results 30mL-2L in Optimum Growth Flasks with ExpiCHO® After Transfection, Presented by Jordan L., Thomson Instrument Company

A095: SIEVEWELL: High Throughput Secretion Based Single Cell Screening for Antibody Discovery, Presented by Takashi O., Tokyo Ohka Kogyo Co., Ltd.

A096: VHH Antibody Discovery Leveraged by Synthetic DNA Technologies, Presented by Lynette T., Twist Bioscience

A097: Rapid Discovery of Hundreds of Rabbit mAbs with High Affinity and Cell Binding Against CD19 Utilizing the Beacon Optofluidic Platform, Presented by Jennifer W., Twist Bioscience

A098: Antibody Discovery from Immune VHH Library Using Yeast Surface Display, Presented by Jeremy W., Twist Bioscience

A099: Maxitope - Revolutionising Antigen Design, Presented by Charles D., University of Edinburgh

A100: Development of Degrader-Antibody Conjugates for Triple-Negative Breast Cancer, Presented by Frederico S., University of Lisbon

A101: Accelerating Therapeutics Discovery: Expressing Human Proteome and Screening Binders in E. coli, Presented by Sayandeep G., University of Oregon

A102: Antibody Therapeutics Targeting the Neuropilin-1 Receptor Domain of VEGFA & PlGF2: New Tools to Parse Cancer Angiogenesis, Presented by Samuel B., University of Texas at Austin

A103: Reliable In Silico T Cell Activation Prediction for Neoantigens Close to Self-Peptidome, Presented by Piotr G., University of Warsaw

A104: CoCUT&Tag Maps the Physical Association of Multiple Proteins on the Genome at a Single-Molecule and Single-Cell Resolution, Presented by Emma B., Van Andel Institute

A105: VTS118-TriAb for Severe SLE and Other B Cells or Autoantibody Associated Severe Autoimmune Diseases, Presented by Man X., Velavigo (Shanghai) Ltd.

A106: Investigating Single-Cell Foundation Models for Drug Target Prioritization, Presented by Siddharth A., Visterra, Inc.

A107: TFC Quick ‘n’ Clean: Next-Gen Platform for High-Throughput Production of True Four-Chain BsAbs, Presented by Mingming S., WuXi Biologics

A108: High-Throughput Identification and Characterization of Patient-Derived Monoclonal Autoantibodies in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Presented by Anjali P., Yale University

A109: Covalently Controlled Conditional Immunocytokine Cancer Therapy; Silent in the Periphery, Super Active in the Tumor, Presented by Sue T., Depth Charge SAS

A110: Robust Physics-Based Methods for Accurate In Silico Prediction of pH-Dependent Protein-Protein Binding Affinities, Presented by Jared S., Schrödinger, Inc.

POSTER SESSION B: Tuesday (afternoon) - Wednesday

B001: Engineering High-Affinity, Developable Antibodies with AlphaBind – A Deep Learning Affinity Oracle, Presented by Miranda L., A-Alpha Bio

B002: Seqitope: High-Resolution, High-Throughput Epitope Mapping Supporting Affinity Maturation Strategies, Presented by Ionut D., AAX Biotech AB

B003: Innovative Platform for Functional Antibody Discovery Against Challenging Membrane Protein Targets, Presented by Xiaofeng L., AbbraTech, Inc.

B004: Comparing Potential Bispecific Formats of Trastuzumab and a Humanized OKT3, Presented by Michael F., Absolute Biotech

B005: Generation of CD28 Costimulatory Heavy Chain-Only Antibodies Using a Synthetic, Yeast-Based Platform for Their Discovery and Engineering, Presented by Ean S., Adimab LLC

B006: A Simple SPR Solution for Complex Samples, Presented by Ludovic L., Affinité Instruments

B007: Accurate Prediction of Antibody-Antigen and Protein-Protein Complex Structure Accelerates Next-Gen Biologics Development, Presented by Kyle K., Ailux Biologics by XtalPi

B008: Corynex® for Next-Generation Biologics: ncAA Incorporation Enables Versatile VHH Conjugation, Presented by Yumi N., Ajinomoto Co., Inc.

B009: Super Naïve OPAL Libraries™: A New Tool for Rapid VHH Discovery, Presented by Philippe V., Antibody Design Labs

B010: High-Throughput Screening of Antibody Developability Properties Using a Neuromorphic Sensing Platform, Presented by Alec T., Apoha Ltd.

B011: Advancing a Polar Metabolomics Workflow to Enhance Therapeutic Protein Expression and Modulate Quality Attributes, Presented by Nathaniel B., Asimov, Inc.

B012: High Efficiency B-Cell Culturing Platform for Rapid Antibody Discovery, Presented by Shailendra U., Aurigene Pharmaceutical Services

B013: Legumain-Cleavable Topoisomerase-1 Inhibitor ADCs Show Reduced Hydrophobicity and Elicit Robust Efficacy in a Pancreatic Cancer Model, Presented by Victor O., Binghamton University, State University of New York

B014: BCG027: A Novel Bispecific Antibody-Drug Conjugate Targeting SEZ6 and B7-H3 for Small Cell Lung Cancer, Presented by Benny Y., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

B015: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Haoming Z., Biointron

B016: TrailBlazer: A Rapid Modular Antibody Assembly Platform, Presented by Erika H., Bio-Rad Laboratories

B017: Elevating Protein Purification Efficiency: Transitioning from Manual Techniques to Automated Platforms, Presented by Gabrielle K., Biotage US

B018: Custom Workflows Accelerate Immunoassay Development with High-Content Biophysics and Modeling, Presented by Nidhi N., Bio-Techne

B019: Biotherapeutic Charge Variant Fractionation Using MauriceFlex™, Presented by Damon P., Bio-Techne

B020: Empowering the Development of TCR-T Cells for Adoptive Cell Therapy, Presented by Yuxia Z., BPS Bioscience

B021: Instant Large-Scale Electroporation for Fast Expression of Antibodies, Presented by Jian C. & George S., Celetrix

B022: Developing an mRNA-Encoded Antibody Platform to Accelerate Therapies to Clinic, Presented by Donna B., Charles River Laboratories

B023: Structure-Based Charge Calculations for Predicting Properties and Profiling Antibody Therapeutics, Presented by Nels T., Chemical Computing Group

B024: Development of a New ADC Platform Designed by Antibody Mimetic Drug Conjugate, Presented by Akira S., CompleCure, Inc.

B025: Engineered Novel CD155 and Nectin-4 Homodimer Proteins Dramatically Enhance Binding Affinities to Their Receptor TIGIT Compared to Respective Monomers, Presented by Peter L., Conigen Bioscience

B026: A New Era in Drug Development Targeting the Most Pivotal Class of Proteins – Introducing an Automated Platform for the Solubilization and Purification of Membrane Proteins, Presented by Barbara M., Cube Biotech GmbH

B027: Advanced Injection Tools Enable the Study of Complex Biological Processes, Presented by Shahab BA., Cytiva

B028: Unveiling the Complementary Benefits of Cas-CLOVER Dimeric Nuclease and Harbor-IN License Free Transposase, Presented by Koy S., Demeetra AgBio

B029: B Cell Screening Using TroVo, Presented by Qi Z., Enrich Biosystems, Inc.

B030: Bioinformatics at FairJourney Biologics: Antibody In Silico Risk Assessment (ISRA), Presented by Jose P., FairJourney Biologics

B031: From Binding to Biology: Dissecting Fc–FcRn Interactions to Drive Antibody Half-Life Design, Presented by Ines S., FairJourney Biologics

B032: Demonstrating Key Processes of the T Cell Therapy Workflow in Chemically Defined Media, Presented by Deborah M., FUJIFILM Irvine Scientific

B033: Precise, Specific, and Sensitive De Novo Antibody Design Across Multiple Cases, Presented by Taeyong P., Galux, Inc.

B034: Fully Automated Candidate Creation Workflow for Intact Mass Mapping of Oligonucleotide Therapeutics, Presented by Maurizio B., Genedata AG

B035: A Digital Platform for the Development of Next-Generation Antibody Drug Conjugates (ADCs) and Other Antigen-Targeting Conjugates, Presented by Matthew P., Genedata AG

B036: A Novel Modular Platform for Conditional Cytokine Activation, Presented by Travis M., Genentech

B037: High-Throughput Protein Structural Analysis with the AutoFox® System: Automated HRPF for Biotherapeutic Insight, Presented by Emily C., GenNext Technologies, Inc.

B038: The FORGE™ Engine Uncovers Tissue-Targeting Moieties for Delivery of Oligonucleotide Therapeutics, Presented by Sunayana N., Gensaic

B039: A High-Throughput Antibody Developability Data Generation Platform for AI/ML Model Training and Drug Discovery, Presented by Ammar A. & Rich C., Ginkgo Bioworks

B040: De Novo Designed Covalent Minibinders for CTLA-4 Blockade, Presented by Helena D., Harvard University

B041: AminoX: Multiplexed Transformation of De Novo Minibinders into Covalent Biologics with User-Defined Non-standard Amino Acids and mRNA Display, Presented by Erkin K., Harvard University

B042: Digital Membrane Chromatography (DMC): Gentle Purification of IgG1 from Cell Culture Without Buffer Exchange, Presented by Ken R., i3 Membrane Corporation

B043: Therapeutic Potential of Novel GAS6-Mediated Anti-Inflammatory Adaptor (GAIA): Overcoming Neuroinflammation via Efferocytosis in Anti-Aß Immunotherapies, Presented by Youngsoo J., Illimis Therapeutics

B044: Development and Optimization of Cost-Effective Non-Human Primate In Vitro Assays for Immunogenicity Screening and Functional Evaluation of Immuno-Oncology Drug Candidates, Presented by Chloe A., ImmunXperts, a IQVIA Laboratories company

B045: 21x Increase in Plasmid Production Yield Compared to Traditional Methods, Presented by Brian L., INFORS HT

B046: High Throughput Development of High-Affinity Fabs and VHH Using Minimalistic Libraries, Presented by Deepash K., Institute for Protein Innovation

B047: A Flexible Automated Workstation for our Antibody Discovery Pipeline, Presented by Curtis W., Institute for Protein Innovation

B048: CDR-Scanning for Antibody Engineering and Patents: Comprehensive CDR Mutagenesis Identifies Residues for Improvements and Enables Antibody Genus Patent Claims, Presented by Soma B., Integral Molecular

B049: Next Generation Conjugates – Site Specific Conjugation of VHH Antibody Modalities, Presented by Jessica K., Isogenica Ltd.

B050: Higher-Order Structure Stability Assessment of Antibody-Drug Conjugate Using CD Spectroscopy, Presented by Yasuo H., JASCO Corporation

B051: Mechanistic Insight into the Immunomodulatory Effects of a Potentiating Antibody Targeting the Interleukin-7 Cytokine, Presented by Emily A., Johns Hopkins University

B052: Design of an Interleukin-2 Based Immunocytokine for Targeted Expansion of Muscle Regulatory T Cells, Presented by Charina F., Johns Hopkins University

B053: High-Performing GMP CRISPR Cas9 Protein for Cell and Gene Therapy, Presented by Yujiao Z., KACTUS

B054: Encapsulation of Oxaliplatin by Exosomes Expressing Anti-EphA2 to Enhance the Therapeutic Effect of Pancreatic Cancer, Presented by Yong-han C., Kaohsiung Medical University

B055: Creating Tumor-Targeting Immune Checkpoint Inhibitors Using Interferon-Based Precursors to Enhance Anti-Cancer Potency and Reduce Systemic Side Effects, Presented by Shi-Wei C., Kaohsiung Medical University

B056: Maximizing Oxaliplatin’s Impact on EGFR+ Colorectal Cancer through Targeted Extracellular Vesicles, Presented by Chia-Tse L., Kaohsiung Medical University

B057: Driving High Titer Production in HEK cells through Cell-line specific Optimization, Presented by Sara S., Kemp Proteins

B058: From Weeks to Days: Turbocharging High-Throughput Antibody Discovery Powered by ALiCE® for HTPE, Presented by Yannick F., LenioBio GmbH

B059: Humanisation of a Mouse Anti-C6 Antibody as a Potential Therapeutic for Complement-Mediated Diseases, Presented by Kathryn A., LifeArc

B060: Novel Synthetic Production Phase Promoter for Enhanced Titre, Product Quality and Expression Stability in CHO Cells, Presented by Alice HC., Lonza

B061: Cell Avidity – The Next-Gen Cell Binding to Understand the Mechanism of Action Through Cell-Cell and Cell-Protein Interaction, Presented by Justin M., LUMICKS

B062: Rapid Discovery and Development of Novel Brain Shuttles for Multiple “Portals” Using Multiplexed In Vivo Screening, Presented by Karen D., Manifold Bio

B063: Immunogenicity Prediction with Dual Attention Enables Vaccine Target Selection, Presented by Song L., Matwings Technology

B064: Antibody-Based Therapeutics for the Treatment of Anti-Platelet Factor 4 (PF4)-Mediated Thrombotic Syndromes, Presented by Anand P., Mayo Clinic

B065: Filling Efficiency Measurements for Gene Therapies Using Total Holographic Characterization, Presented by Jeffery H., Mecuriale LLC

B066: Modulating TREM2-Dependent Signaling via Clustering Using Novel VHs, Presented by Fiona A., Merck & Co., Inc.

B067: EPITOP™ / IMMUNOTOP™: Machine Learning Tools for Predicting Immunogenic Epitopes and Protein Immunogenicity, Presented by Yuri I., ModeX Therapeutics

B068: The ALFA System: One Tag – Three sdAbs – Unlimited Applications, Presented by Hansjörg G., NanoTag Biotechnologies GmbH

B069: High-Throughput Characterisation of Excipients’ Impact on the Physical Stability of Biologics, Presented by Bridget M., NanoTemper Technologies

B070: Glycan Removal from Therapeutic Glycoproteins for Peptide and Intact Mass Analysis Using Rapid PNGase F, Protein Deglycosylation Mix II and Exoglycosidases, Presented by Paula M., New England Biolabs, Inc.

B071: A Human In Vitro Secondary Lymphoid Organ Model to Advance Immune-Modulatory Drug Development, Presented by Elwira K., Nexus BioQuest

B072: Developing a Fully Human CD19 T Cell Engager Using NonaHCAbFx Platform, Presented by Bradley D., Nona Biosciences

B073: Decoding Antibody Behavior: Protein Language Models vs. Traditional Biophysical Parameters for Predicting Non-Specificity, Presented by Ludovica B., Novo Nordisk A/S

B074: Increasing Soluble Protein Yield: Utilizing AlphaFold for Guided Protein Variant Design and Screening, Presented by Chava A., Nuclera

B075: High Throughput Hydrophobicity and Polyreactivity Assays for 6His-Tagged Proteins, Presented by Aris P., PAIA Biotech GmbH

B076: The Discovery and Development of a CD3 Agonistic Single Domain Antibody to Accelerate the Development of CD3 T Cell Engager Multi-Specific Antibodies, Presented by Yu L., ProBio, Inc.

B077: ANKYRONS - Next Generation Target Binding and Detection, Presented by Andrew I., ProImmune

B078: HiBiT Targeted Cell Killing (TCK) Bioassays for Biologics Characterization and Potency Testing, Presented by Alissa K., Promega Corporation

B079: Orthogonal Techniques for LCMS Characterization of a Lysine-Conjugated ADC, Presented by St John S., Protein Metrics

B080: XtenCHO™ Race: High Performance CHO Cells for the Development and Production of New Therapeutic Antibodies, Presented by Gaetan M., ProteoGenix

B081: Standardized Tools for Biologics Analyses and QC: glyPAQ™ and the Turbo MAM Kits, Presented by John W., ProtiFi LLC

B082: Engineering the Next Generation of Antibody Therapeutics Using the Multabody Platform, Presented by Xinwen H., Radiant Biotherapeutics, Inc.

B083: Determining Protein Stability and Structure in One Measurement Using Microfluidic Modulation Spectroscopy (MMS), Presented by Valerie C., RedShiftBio

B084: Diligent Design of Brainshuttle™-ASO Conjugates Enables Peripheral Drug Delivery to the Brain, Presented by Maximilian H., Roche Diagnostics GmbH

B085: Creating Innovative Biological Platforms to Develop Novel Therapies, Presented by Bongmun K., Sookmyung Women's University

B086: High Throughput Single Cell Analysis, Sorting and Dispensing Using Multi-Laser Picodroplet Technology, Presented by Ben D., Sphere Bio

B087: ToxSYN™ Platform to Complement GlycoConnect™ and HydraSpace™ Technologies to Enable Best-in-Class ADCs with Tailored Mode-of-Action, Presented by Sander V., Synaffix BV

B088: Discovery of Anti-SARS-COV2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single Domain Antibodies from a Synthetic Library, Presented by Isamu T., Takeda Pharmaceuticals

B089: ImmunoPET for the Detection of Nectin-4 and TROP2 in Bladder Cancer, Presented by Peter C., Telix Pharmaceuticals

B090: Development of a Novel ADC in Lung Cancer Leveraging a Multiomic Target Discovery Platform, Presented by Daniel M. & Christoph M., TenSixty Bio

B091: Expi293™ PRO Expression System: A Next-Generation Expression System for Higher Yields Across a Wider Variety of Proteins, Presented by Chao Yan L., Thermo Fisher Scientific

B092: Increasing Protein Titer and Achieving Consistent Product Quality in CHO Cells with a Novel Protein-Free Feed System, Presented by Kyle S., Thermo Fisher Scientific

B093: New Mid-Scale Workflows for 20mL - 50mL in Automation Friendly Format, Presented by Sam E., Thomson Instrument Company

B094: Chemotherapy Induces Pro-Invasive Changes in the Extracellular Matrix Produced by Mammary Fibroblasts, Presented by Anna Y., Tufts University

B095: Synthetic Nanobody Library Design and Pharmacodynamic Selection Strategies for Novel Radiopharmaceuticals, Presented by Amber J., University of Alabama at Birmingham

B096: Development of Next-Generation Theranostics by De Novo Protein Design, Presented by Luke R., University of Alabama at Birmingham

B097: Epitope Guided Generation of Anti-Idiotype Antibodies, Presented by Forrest E., University of California, Los Angeles

B098: Automated Optimisation of Solubility and Conformational Stability of Proteins, Presented by Montader A., University of Cambridge

B099: Non-Specificity Fingerprints for Clinical Stage Antibodies in Solution, Presented by Therese H., University of Cambridge

B100: Clinical Potential of Oncofetal-Chondroitin Sulfate for Pan-Cancer VartumAb Antibody-Drug Conjugate Therapy, Presented by Elena V., University of Copenhagen

B101: Generation of S100A8/A9 Nanobodies Using Directed Evolution, Presented by Ece A., University of Michigan

B102: Pharmacokinetic Characterization of Brain Delivery Using Bispecific Antibodies Targeting CD98hc and Transferrin Receptor, Presented by Cecilia S., University of Michigan

B103: Structure-Guided Fc Engineering for Cross-Species FcgR Binding, Presented by Yakendra B., University of Texas at Austin

B104: Deep Mutational Scanning of VRC01 HIV Broadly Neutralizing Antibody Reveals Potential Pathways of HIV Env N276 Glycan Accommodation, Presented by Jamin W., University of Utah

B105: Antibody Discovery for Complex Membrane Antigens, Presented by Ernest S., Vaccinex, Inc.

B106: Novel Light Scattering Methods for Accelerating the Development of ADCs, Presented by John C., Wyatt Technology

B107: Development of Rabbit Anti-Polyethylene Glycol (PEG) Monoclonal Antibodies for Pharmacokinetic Studies of PEGylated Drugs, Presented by Yang L., Yurogen Biosystems

B108: Peptide Radioligand Development via PepLib’s Advanced Peptide Discovery Platform, Presented by Timo X., Zonsen Peplib Biotech

B109: R1-KH, a Bispecific Innate Immune Cell Engager (BIIE), for the Treatment of EBV Infection and EBV-Associated Lymphoproliferative Disorders (EBV-LPDs), Presented by Weiguo Y., Huazhong Agricultural University

B110: Unlocking Latent Phenotypic Predictive Power in Unstructured Molecular Data via Self-Supervised Machine Intelligence, Presented by Mel H., Matterworks, Inc.

POSTER SESSION C: Thursday

C001: The Format Matters: Stabilities of Bispecifics, Presented by Vera M., 2bind GmbH

C002: Rapid Development of Dual Specific Antibodies via Platform Integration, Presented by Leah H., A-Alpha Bio

C003: Large-Scale Evaluation of Inverse Folding Models for De Novo Antibody Design Using High-Throughput Binding Affinity Assays, Presented by Adrian L., A-Alpha Bio

C004: CB2 Specific Antibody Agonists for Treatment of CIPN and Liver Fibrosis, Presented by Swastik S., Abalone Bio

C005: Streamlining Antibody Discovery: Rational Libraries, Targeted Mutagenesis, High-Resolution Screening, and Recombineering, Presented by Michael W., AbbraTech, Inc.

C006: Strategies for Tailoring T-Cell Engager Design for Solid Tumor Indications, Presented by Mihai C., AbCellera

C007: AbiLeap™: Systematically Generate Conditionally Active Biotherapeutics, Presented by Jean-Philippe B., Ability Biologics

C008: Development of a Platform Approach to Identify the Most Functional and Developable Bispecific T-Cell Engager, Presented by Campbell B., Abzena

C009: Rapid Developability Assessments to Assist Lead Candidate Selection, Presented by Edward C., Abzena

C010: Accelerating Novel Drug Modality Development by AJICAP® Site-Specific Chemical Conjugation Technology, Presented by Tsubasa A., Ajinomoto Co., Inc.

C011: Expanding Therapeutic Windows of ADCs Enabled by AJICAP® Site-Specific Chemical Conjugation and Hydrophilic Linker Technology, Presented by Hiroki I., Ajinomoto Co., Inc.

C012: A VEGF / 4-1BB Bifunctional Therapeutic Couples VEGF Binding to Allosteric 4-1BB Activation, Programming Robust Innate and Adaptive Antitumor Immunity, Presented by Michelle Y., Ampersand Biomedicines

C013: Sensitive Circular Dichroism Analysis of Therapeutic Antibodies, Presented by Brandon M., Applied Photophysics, Inc.

C014: Complete Thermal Melting Characterization of the NISTmAb with the SUPR-DSF Microplate Reader, Presented by Brandon M., Applied Photophysics, Inc.

C015: Automating Protein Stability Screening: Enhancing Throughput and Accuracy with SUPR-DSF, Presented by Frank Y., Applied Photophysics, Inc.

C016: EPPI_ddg: Predicting Changes in Binding Free Energy from Point Mutations Using a Structure Based Feature Space and Random Forest, Presented by Clay R., Auburn University

C017: Developing a Predictive Model for ΔΔG in Protein-Peptide Binding, Presented by Jazmine T., Auburn University

C018: Purification Strategies for Transmembrane Proteins Sp1 and Sp2  for Safety Evaluation, Presented by Wenguang L., Bayer CropScience

C019: CRISPR/Cas9-Based Precision B Cell Gene Engineering Coupled with Artificial Intelligence-Guided Protein Design Produces Active Tissue Nonspecific Alkaline Phosphatase for the Treatment of Hypophosphatasia, Presented by Monika MS., Be Biopharma, Inc.

C020: GL-DisacLink:A Promising Technology for Glycosite-Specific Conjugation, Presented by Lily Y., BioDlink (TOT BIOPHARM)

C021: Extracellular Vesicle Isolation and Analysis, Presented by Ertan O., Bio-Rad Laboratories

C022: Rapid Generation of Bispecific Antibodies for High Throughput Screening with SpyLock Technology, Presented by Francisco Y., Bio-Rad Laboratories

C023: Accelerated Assessment of AAV Titer, Quality, Potency with Automated Analytical Tools, Presented by Peter J., Bio-Techne

C024: Engineering Cell and Gene Therapy Reagents, Presented by David N., Bio-Techne

C025: Optimization of Plate Based CHO Expression and Protein A Purification Technologies to Support Early-Stage Biotherapeutic Discovery, Presented by Zhong-Fu H., Boehringer Ingelheim Pharmaceuticals, Inc.

C026: Dedicated Computational Methods for Feature Detection and Quantification in Large Molecule Mass Spectrometry Analyses, Presented by Gary W., Dotmatics

C027: Enabling Research Tools for αß and γδ T Cell-Based Immunotherapy, Presented by Michelle K., BPS Bioscience

C028: Characterization of Antibody-Based Therapeutics Using Charge-Based and Sized Based Microfluidic Electrophoresis, Presented by Jenna R., Brown University

C029: HT-SPR Evaluation of Fc Gamma Receptor Binding Using Carterra LSAXT, Presented by Nicholas A., Carterra

C030: Generation of a B7-H3 Knock Out Cell Line: Validation for Off-Target Screening Using the Retrogenix® Cell Microarray Platform, Presented by Sarah D., Charles River Laboratories

C031: Production of Starch-Modifying Enzymes, Presented by Kuakarun K., Chulalongkorn University

C032: A Tunable and Scalable Platform for Precise Fucosylation Control to Enhance Efficacy of Therapeutic Antibodies: Application to Clinical Manufacturing of Budoprutug, Presented by Gary H., ClimbBio

C033: Engineered Immune Checkpoint CD28 and CTLA-4 Homodimer Proteins Demonstrate Potent Binding Affinities to Their Ligand CD80, Presented by Jean Q., Conigen Bioscience

C034: Recombinant Expression Validates De Novo Sequencing Accuracy: Trastuzumab and Anti-Factor XII Case Study, Presented by Ryan W., CovalX Instruments, Inc.

C035: Optimized Transient Production: Faster Preclinical Studies with Enhanced Quality Control, Presented by Kexin H., Curia

C038: Machine Learning Guided Interaction Analysis, Presented by Reuben R., Fluidic Sciences Ltd.

C039: Chemically Defined BalanCD HEK293 Viral Feed Boosts Viral Vector Production, Presented by Robyn S., FUJIFILM Irvine Scientific

C040: Future Fields' EntoEngine™: Revolutionizing Recombinant Protein Production with Transgenic Drosophila, Presented by Jeremy J., Future fields IO

C041: An Automated High Throughput Engineering Platform for AI-Supported Developability Predictions, Presented by Jacob W., Genedata AG

C042: Modulation of the High Concentration Viscosity of IgG[1] Antibodies Using Clinically Validated Fc Mutations, Presented by Joel H., Genentech

C043: Accelerating Antibody Discovery: High-Throughput Solutions for Producing Antibodies at Scale, Presented by Riley G., GENEWIZ from Azenta Life Sciences

C044: Predicting and Generating Developable Antibodies with Protein Language Models, Presented by Porfirio QC. & Josh M., Ginkgo Bioworks

C045: Hydrophilic Stabilized Glycopeptide Linker Enables Novel Topoisomerase 1 Inhibitor and Dual-Payload ADCs, Presented by Juhani S., Glykos Finland Ltd.

C046: High-Sensitive Immunopeptidomics for Identification of Neoantigens and Validation of MHC Presentation of (Predicted) Antigens, Presented by ImmuneSpec

C047: AI-Driven Development of pH-Selective Antibodies Targeting Human FOLR2 for Tumor-Specific Therapy, Presented by Li H., ImmunoPrecise Antibodies Ltd. (IPA)

C048: Advancing Bispecific Lead Generation Through Integrated In Vivo and In Silico Approaches to Drive Clinical Success, Presented by Shuji S., ImmunoPrecise Antibodies Ltd. (IPA)

C049: TPIPE, a Pipeline for the Identification and Functional Assessment of Therapeutic Cancer Vaccine Candidates, Presented by Sofie P., ImmunXperts, a IQVIA Laboratories company

C050: High-Throughput Characterization and Validation of Reagent Antibody Tools for Neurexin-Neuroligin Receptor Families, Presented by Murali A., Institute for Protein Innovation

C051: H5N1 Pandemic Preparedness: Building a Comprehensive Immunological Toolbox, Presented by Martine B., IQVIA Laboratories

C052: Click Chemistry-Driven Method Development for Antibody Conjugates, Presented by Kyoung-Soo C., Johnson & Johnson Innovative Medicine

C053: An Ultra High-Throughput Method to Generate a Large Conformational Thermostability Dataset via Phage-Display, Presented by Michael S., Just - Evotec Biologics

C054: Rapid Acceleration of Multispecific Ab Discovery and Development Using Eukaryotic Cell-Free Expression System, Presented by Ridhima G., LenioBio GmbH

C055: Building Therapeutic Antibody Discovery Capabilities for Challenging Targets, Presented by Beth W., LifeArc

C056: Advancements in Antibody Discovery Through High-Throughput Droplet Microfluidics: Integrating Innovative Antibody Detection Assay with ModaFlow™ for Enhanced Therapeutic Development, Presented by Stephanie V., LiveDrop

C057: Engineering TEV Protease Specificity with Machine Learning and a New Ultra-High-Throughput Assay, Presented by Vikram S. & Boqiang T., Massachusetts Institute of Technology

C058: Discovery of Expression-Governing Residues in Proteins, Presented by Shi L., Matwings Technology

C059: Purification, and Characterization of Lumazine Synthase Nanoparticles in Mammalian Cell Line, Presented by Gwenny G., Merck & Co., Inc.

C060: Robust High-Throughput Sample Preparation for Early Discovery Protein Characterization, Presented by Jonathan H., Merck & Co., Inc.

C061: A Data Platform and AI/ML-Driven Strategy to Accelerate Next-Generation Sequencing Analysis in Phage/Yeast Display, Presented by Rizki M., Merck & Co., Inc.

C062: Accelerating Antibody Screening and Engineering with Automated High-Throughput Production Solutions and AI/ML-Driven Protein Design, Presented by Kendal W., Merck & Co., Inc.

C063: MACS Matchmaker: Biomolecular Interaction Analysis in Real Samples Label-Free, in Real-Time – Here Comes Focal Molography, Presented by Michael W., Miltenyi Biotec B.V. & Co. KG

C064: Antibody-Drug Conjugates with Novel Payloads Are Enabled by an Ultra-High DAR Platform, Presented by Antonina S., Myris Therapeutics

C065: Introducing NEBExpress® Salt Active Nuclease for Nucleic Acid Removal in Purification Workflows, Presented by Carine RI., New England Biolabs, Inc.

C066: Enabling De Novo Antibody Discovery from AI-Designed Libraries, Presented by Pavel N., OCMS Bio

C067: Native RPLC-HRMS Method Development Approach for the Rapid Characterization of Antibody Drug Conjugates, Presented by Carl S., Phenomenex, Inc.

C068: Directed Luck®: Transposase Targeting and Transposon Design Push Expression Beyond Limits, Presented by Anneliese K., ProBioGen AG

C069: Luminescent Fc Gamma Receptor Assays for ADCP and ADCC Characterization to Guide the Development of Antibody Therapeutics, Presented by Andrew Z., Promega Corporation

C070: Advancements in Multi-Protein Quantitation for Host Cell Protein Discovery, Presented by William R., Protein Metrics

C071: Synergizing Protein Diffusion Models and Cryo-EM Innovations: Tackling Beta-Barrel Solubilization via Protein Engineering, Presented by Wouter V., PUXANO

C072: Rapid, Animal-Free Discovery of Single-Domain Antibodies from a Novel Synthetic Library, Presented by Robert D., Quantitative BioSciences, Inc.

C073: Nanobody Hot Spot Residue Identification and Epitope Binning with AI Structural Prediction, Presented by Marc S., Sandia National Laboratories

C076: Freeze-Thaw Induced mAb Aggregation: A Small-Volume Approach to Simulate Manufacturing, Presented by Miguel R., Smartfreez

C077: Highly Potent, Bispecific ADCs by Application of Clinical Stage GlycoConnect® Technology to bYlok® Antibodies, Presented by Lieke K., Synaffix BV

C078: proPBD-ADCs: Optimization of Therapeutic Potential of ADCs Based on Capped PBD Payload with Attenuated Potency, Presented by Remon V., Synaffix BV

C079: Enhancing Protein Stability: The Role of Thermal Analysis in Formulation, Presented by Christine N., TA Instruments

C080: A Novel Deep Learning Approach for Predicting Stability of Proteins upon Single Point Mutations, Presented by Sadhna R., Tata Consultancy Services

C081: High-Throughput Methods for Monitoring Antibody Internalization and Lysosomal Degradation Using a Cathepsin-Activated Sensor and Site-Specific Conjugation, Presented by Chris L., Thermo Fisher Scientific

C082: Power Meets Precision | HTP Antibody Production with Expi™ Protein Expression Systems & GeneArt HTP Antibody Production, Presented by Matt M., Thermo Fisher Scientific

C083: Automation of the Expi293™ PRO Expression System for High Titer, High Throughput Protein Production at the 96 Well Scale, Presented by Collin R., Thermo Fisher Scientific

C084: Thomson 7L Flask Replacing Bioreactor and Cell Bags Between 5L to 6L/Flask - Ability to Grow Up to 35L/Shaker, Presented by Alec P., Thomson Instrument Company

C085: TRIV-573, a Bispecific Antibody Combining KLK5/KLK7 and IL-13 Inhibition to Rebalance Barrier Dysfunction and Inflammation in Atopic Dermatitis, Presented by Chris N. & Jason H., Triveni Bio

C086: Mesothelin-Targeted Nanobody-Drug Conjugates to Treat Pancreatic Cancer, Presented by Nisita D., University of Cambridge

C087: Prediction of Protein Biophysical Traits from Limited Data: A Case Study on Nanobody Thermostability Through NanoMelt, Presented by Aubin R., University of Cambridge

C088: IKS04: A Novel CanAg-Targeting Antibody-Drug Conjugate with Pyrrolobenzodiazepine (PBD) Prodrug Payload, Shows Enhanced Efficacy with Isumab04 Antibody Coadministration in Preclinical Models, Presented by Haolong H., University of Michigan

C089: LICHEN: Light-Chain Immunoglobulin Sequence Generation Conditioned on the Heavy Chain and Experimental Needs, Presented by Henriette C., University of Oxford

C090: Predicting the Developability of Nanobodies to Improve Therapeutic Design, Presented by Gemma G., University of Oxford

C091: Towards Better Therapeutics: Evaluating Computationally Humanized Antibodies, Presented by McKenna F., University of Texas at Austin

C092: scFvs: Targeting Snake Venom Phospholipase A2 and Serine Protease, Presented by Ying J., University of Texas Rio Grande Valley

C093: Innovative Assays and Kits for Antibody Drug Development, Presented by Joe Z., Vazyme Biotech Co., Ltd.

C094: Re-Engineering SARS-CoV-2 Antibodies Using a Supervised Machine Learning Approach, Presented by Tomasz K., Washington University

C095: High Sensitivity Titer & 2D Protein A-SEC Analysis for Faster Quantitation of mAb Titers and Aggregates, Presented by Michael Z., Waters Corporation

C096: Micro Developability: High-Throughput Developability Assessment for Early-Stage Lead Optimization, Presented by Doris W., WuXi Biologics

C097: An Integrated Approach to Accelerate the ADC Discovery with WuXi XDC Innovative Technology Toolbox, Presented by Rachana O., WuXi Biologics

C098: CrossBody: An Innovative Multispecific Antibody Platform to Overcome On-target, Off-Tumor and Cytokine Release Syndrome Toxicity, Presented by Xiaoyan L., XTOP Biotherapeutics LLC

C099: Enhancing Antibody Discovery Single-Cell Immune Repertoire Sequencing and Artificial Intelligence, Presented by Hao C., Yurogen Biosystems

2025 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology & Beyond
• Driving Clinical Success in Antibody-Drug Conjugates

• TS: Intro to Multispecific Antibodies
• Advancing Multispecific Antibodies
• Engineering Bispecific and Multifunctional Antibodies

• Advances in Immunotherapy
• Engineering Cell Therapies
• Next-Generation Immunotherapies

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Maximizing Protein Production Workflows

• ML and Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Predicting Immunogenicity with AI/ML Tools
• TS: Bioassay Development and Analysis

• Biologics for Immunology Indications
• Radiopharmaceutical Therapies
• Next-Generation Immunotherapies

• ML and Digital Integration in Biotherapeutic Analytics
• Predicting Immunogenicity with AI/ML Tools
• Machine Learning for Protein Engineering